Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients.
Jana UlehlovaBarbora PisklákováEliška IvanovováJana ProcházkováPavla BradacovaAleš KvasničkaDavid FriedeckýLuděk SlavíkPublished in: Diagnostics (Basel, Switzerland) (2021)
The acute findings of the presence of LA-type antibodies fundamentally affects the determination of DOAC by functional tests, and in this case, it is necessary to use LC-MS analysis to determine the true value. If patients treated with DOAC develop LA of medium and higher titers, we do not recommend checking DOAC levels with functional tests.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- ejection fraction
- systemic lupus erythematosus
- newly diagnosed
- chronic kidney disease
- solid phase extraction
- peritoneal dialysis
- prognostic factors
- pulmonary embolism
- respiratory failure
- intensive care unit
- disease activity
- liquid chromatography